Xeris Biopharma Holdings, Inc. Share Price Nasdaq
Equities
XERS
US98422L1070
Pharmaceuticals
Sales 2024 * | 184M 15.38B | Sales 2025 * | 219M 18.29B | Capitalization | 259M 21.63B |
---|---|---|---|---|---|
Net income 2024 * | -55M -4.59B | Net income 2025 * | -27M -2.25B | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.18 x |
P/E ratio 2024 * |
-4.55
x | P/E ratio 2025 * |
-9.55
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.26% |
Latest transcript on Xeris Biopharma Holdings, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 01/05/01 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05/21/05 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05/21/05 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05/21/05 |
Marla Persky
BRD | Director/Board Member | 68 | 05/21/05 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |